Dr. Finman earned a B.S. in Statistics from the State University of New York at Oneonta and a Ph.D. in Biostatistics from the Medical College of Virginia/Virginia Commonwealth University School of Medicine. His 35+ years of experience in drug development spans clinical trial design, conduct reporting, oversight, and defense of regulatory submissions.
Dr. Finman spent 24 years at Pfizer earning additional responsibilities and building his reputation as a trusted and respected statistician with experience in the oversight of clinical statistics, statistical programming, data management, and project managers in the Biometrics department.
Dr. Finman’s clinical trial experience spans Phase I to Phase III and through registration across a broad range of therapeutic areas and indications, for numerous NDA submissions that resulted in FDA approval, including applications for in-license and co-development submissions.
In 2009, Dr. Finman founded Jupiter Point Pharma Consulting, LLC. The firm provided statistical input for drug development programs, including the design, analysis, interpretation, and defense of clinical trials in support of regulatory submission for a wide variety of programs and companies around the world. As part of a long-standing collaboration with CRC (prior to his role as Chief of Biostatistics), Dr. Finman also has expertise in the design and analysis of driving studies using CRC’s customized driving simulator. The firm was acquired by Cognitive Research Corporation in 2022.
In addition to providing oversight for the Statistics and Statistical Programming groups at CRC, he provides technical statistical support for sponsor organizations in the planning, execution, and analysis of clinical studies and development programs. He routinely provides strategic support for regulatory interactions and participates in meetings with sponsors and regulatory agencies, including sponsor representation in FDA Advisory Committee Meetings. He also has considerable experience serving on and in chartering Safety Review Committees and Data Safety Monitoring Boards.
He is a board member of Hope in Focus, a nonprofit patient advocacy organization dedicated to generating awareness, raising funds for research, and providing support, education, and outreach to the Leber Congenital Amaurosis and rare inherited retinal disease community. He is also a member of the American Statistical Association and the International Society for CNS Clinical Trials and Methodology.
When he can find the time, Dr. Finman enjoys boating, playing the piano, and woodworking.